NCT06323213View on ClinicalTrials.gov

Efficacy and Safety Study of 610 in Patients With Severe Asthma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

480

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Asthma

Interventions

DRUG

610

610 subcutaneously injection.

DRUG

Placebo

Placebo subcutaneously injection.

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY